Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
    • Transskriptioner
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Xvivo Perfusion

183,60 SEK

+4,44 %

Mindre end 1K følgere

XVIVO

NASDAQ Stockholm

Medical Equipment & Services

Health Care

Oversigt
Finansielt overblik og estimater
Ejerskab
Dividend
Investorkonsensus
Sammenligne
+4,44 %
-13,23 %
-1,61 %
+6,99 %
+12,02 %
-57,10 %
-22,37 %
-43,16 %
+866,32 %

Xvivo Perfusion operates in the medical technology industry and focuses on the development and manufacturing of systems for organ transplantation and perfusion. Examples of products that the company supplies include cannulas, organ storage and cooling solutions. The company's products are aimed at healthcare institutions and surgeons. Xvivo Perfusion operates globally, was founded in 1998 and is headquartered in Gothenburg, Sweden.

Læs mere
Markedsværdi
5,78 mia. SEK
Aktieomsætning
14,22 mio. SEK
Omsætning
812,17 mio.
EBIT %
10,88 %
P/E
229,5
Udbytteafkast, %
-
Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
24.4
2026

Delårsrapport Q1'26

27.4
2026

Generalforsamling '26

14.7
2026

Delårsrapport Q2'26

Alle
Selskabspræsentationer
Selskabsmeddelelser
ViserAlle indholdstyper
Selskabsmeddelelse20.2.2026, 13.24

Correction: The Nomination Committee’s proposal for new board members

Xvivo Perfusion
Selskabsmeddelelse20.2.2026, 13.00

The Nomination Committee of XVIVO Perfusion AB (publ) proposes Emil Billbäck and Anne-Karen Hunt as new members of the Board of Directors

Xvivo Perfusion
Selskabsmeddelelse19.2.2026, 15.45

Management change at XVIVO – CFO transitions to new role

Xvivo Perfusion

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Pressemeddelelse10.2.2026, 14.00

Change of date for publication of the Interim report January-March 2026

Xvivo Perfusion
Pressemeddelelse28.1.2026, 10.06

Redeye: XVIVO (Q4 interview) - Redeye talks with CEO Christoffer Rosenblad

Xvivo Perfusion
Pressemeddelelse28.1.2026, 09.03

Redeye: Xvivo Perfusion (Q4 Review) - Setting up for a strong 2026

Xvivo Perfusion
Xvivo, Audiocast, Q4'25
Videopræsentation27.1.2026, 13.00

Xvivo, Audiocast, Q4'25

Xvivo Perfusion
Selskabsmeddelelse27.1.2026, 06.30

Year-End Report 2025

Xvivo Perfusion
Pressemeddelelse22.1.2026, 13.00

Modular Finance IR Consensus: XVIVO Perfusion – Consensus estimates Q4 2025

Xvivo Perfusion
Pressemeddelelse15.1.2026, 13.30

Conference call on Year-end Report 2025

Xvivo Perfusion
Pressemeddelelse6.1.2026, 13.45

XVIVO’s CEO to present at J.P. Morgan’s 44th Annual Healthcare Conference in San Francisco

Xvivo Perfusion
Pressemeddelelse27.10.2025, 13.29

Redeye: Xvivo Perfusion - And the beat goes on

Xvivo Perfusion
Xvivo, Audiocast, Q3'25
Videopræsentation23.10.2025, 12.00

Xvivo, Audiocast, Q3'25

Xvivo Perfusion
Selskabsmeddelelse23.10.2025, 05.30

Interim report January–September 2025

Xvivo Perfusion
Pressemeddelelse20.10.2025, 12.30

Modular Finance IR Consensus: XVIVO Perfusion – Consensus estimates Q3 2025

Xvivo Perfusion
Pressemeddelelse13.10.2025, 17.00

Conference call on Interim Report July-September 2025

Xvivo Perfusion
Pressemeddelelse5.9.2025, 12.30

Nomination Committee of XVIVO Perfusion AB (publ)

Xvivo Perfusion
Selskabsmeddelelse28.7.2025, 20.10

Delay in CE approval for XVIVO’s perfusion solution for heart preservation

Xvivo Perfusion
Pressemeddelelse21.7.2025, 07.00

First patient enrolled in US PRESERVE CAP study for XVIVO Heart Assist Transport device

Xvivo Perfusion
Pressemeddelelse15.7.2025, 08.40

Redeye: XVIVO - A major challenge triggers a major opportunity

Xvivo Perfusion
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.